ASPE Observations on US trends in Rx drug prescribing

9 March 2016

The USA’s Office of the Assistant Secretary for Planning and Evaluation (ASPE) this week released its Observations on trends in prescription drug spending, noting that expenditures on Rx medicines are rising and are projected to continue to rise faster than overall health spending thereby increasing this sector’s share of health care spending.

Other key findings

• ASPE, a part of the Department of Health & Human Services, estimates that prescription drug spending in the USA was about $457 billion in 2015, or 16.7% of overall personal health care services. Of that $457 billion, $328 billion (71.9%) was for retail drugs and $128 billion (28.1%) was for non-retail drugs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK